Trexquant Investment LP Purchases 27,331 Shares of SiBone $SIBN

Key Points

• Trexquant Investment LP increased its stake in SiBone by 31.1%, owning approximately $1.62 million worth of shares as of its latest SEC filing.
• Insider Anthony J. Recupero sold 3,833 shares at an average price of $15.62, resulting in a decrease in his ownership by 1.37%.
• SiBone reported a quarterly revenue of $48.63 million, exceeding analysts' expectations, with an EPS of ($0.14), beating the consensus estimate of ($0.19).

Trexquant Investment LP lifted its holdings in SiBone (NASDAQ:SIBN - Free Report) by 31.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 115,114 shares of the company's stock after buying an additional 27,331 shares during the quarter. Trexquant Investment LP owned approximately 0.27% of SiBone worth $1,615,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SIBN. ANTIPODES PARTNERS Ltd purchased a new stake in shares of SiBone in the 1st quarter worth about $34,000. Virtus Fund Advisers LLC purchased a new stake in SiBone during the 4th quarter valued at about $40,000. GAMMA Investing LLC grew its position in SiBone by 20,352.6% during the 1st quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock valued at $55,000 after purchasing an additional 3,867 shares during the last quarter. Virtus Advisers LLC purchased a new stake in SiBone during the 1st quarter valued at about $58,000. Finally, Johnson Investment Counsel Inc. purchased a new stake in SiBone during the 1st quarter valued at about $148,000. 98.11% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on SIBN shares. Cantor Fitzgerald set a $25.00 price objective on shares of SiBone and gave the company an "overweight" rating in a research report on Monday, August 11th. Wall Street Zen downgraded shares of SiBone from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, SiBone presently has a consensus rating of "Buy" and an average price target of $23.67.

Insider Transactions at SiBone

In other news, CFO Anshul Maheshwari sold 5,005 shares of the stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $18.34, for a total value of $91,791.70. Following the transaction, the chief financial officer owned 217,078 shares in the company, valued at $3,981,210.52. This represents a 2.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director John Gordon Freund sold 12,132 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $15.99, for a total transaction of $193,990.68. Following the completion of the transaction, the director owned 91,767 shares in the company, valued at $1,467,354.33. This trade represents a 11.68% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 46,590 shares of company stock worth $765,137. 4.00% of the stock is currently owned by corporate insiders.

SiBone Stock Performance

Shares of NASDAQ:SIBN traded up $0.66 during trading on Thursday, hitting $16.32. The company's stock had a trading volume of 570,959 shares, compared to its average volume of 298,153. The company has a 50-day moving average of $16.68 and a 200-day moving average of $16.45. SiBone has a 12 month low of $11.70 and a 12 month high of $20.05. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.38 and a quick ratio of 7.00. The firm has a market cap of $704.04 million, a price-to-earnings ratio of -29.14 and a beta of 0.81.

SiBone (NASDAQ:SIBN - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.05. SiBone had a negative net margin of 12.83% and a negative return on equity of 14.20%. The firm had revenue of $48.63 million for the quarter, compared to analysts' expectations of $48.12 million. SiBone has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that SiBone will post -0.78 earnings per share for the current year.

SiBone Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.